Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse
2d agoen
From the article
Conditions : Acute Myeloid Leukemia (AML); Maintenance Treatment; Hematopoetic Stem Cell Transplantation Interventions : Drug: Lisaftoclax Plus Azacitidine Sponsors : Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
reuters.com·1mo ago
Donor-derived stem cell memory CAR T cells show enhanced expansion and safety in post-HSCT relapse treatment
This first-in-human study (NCT01087294) investigates donor-derived CD19-CAR T cells for treating B cell malignancies relapsing after allogen
cell.com·8d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.